What the sermorelin literature actually says

Before the long read

Sermorelin's mechanism is specific and well-understood: it binds one receptor on one type of pituitary cell and prompts that cell to release growth hormone in a pulse. Because the pituitary stays in charge, the body's normal braking signals — somatostatin and IGF-1 (insulin-like growth factor 1, the hormone the liver makes in response to growth hormone) — still work ^[1][8]. The human evidence breaks into three clear chapters: a 1990s registration record in children with growth-hormone deficiency, a small set of elderly-adult trials showing GH and IGF-1 restoration, and a 2012 cognition trial ^[3][4][16]. Outside those lines the literature thins quickly. This page walks each chapter in order, so you can see what was actually studied and what was not.

Mechanism — a small, specific signal

Sermorelin acts on a single receptor in a single tissue. It binds the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary ^[1]. Binding activates a Gs / adenylate cyclase / cAMP / PKA cascade, which raises growth hormone gene transcription and promotes pulsatile GH release ^[1]. Downstream, the released GH drives hepatic IGF-1 production through JAK2/STAT5, and circulating IGF-1 closes the loop with negative feedback to the pituitary and hypothalamus ^[1][8].

This matters for two practical reasons. First, the pituitary remains the gatekeeper: if endogenous somatostatin or IGF-1 are signalling "enough," the pituitary does not over-release in response to a GHRH analog ^[9]. Second, in the original sermorelin clinical record submitted with the NDAs, the molecule produced isolated GH-axis activation — no measurable changes in prolactin, LH, FSH, insulin, cortisol, glucose, glucagon, or thyroid hormones ^[7]. The signal is narrow.

Why intermittent dosing is the protocol

The 2020 secretagogue review by Ishida and colleagues is the clearest modern summary of why the published protocols are intermittent rather than continuous. Continuous infusion of GHRH causes tachyphylaxis — a rapid loss of pituitary response as receptor signalling adapts ^[9]. Intermittent dosing (a single nightly subcutaneous injection 30 to 45 minutes before sleep is the most common research protocol) preserves the sleep-entrained, pulsatile pattern of GH release that the body itself uses, and avoids the desensitization seen with continuous exposure ^[9].

This is also why sermorelin's pharmacology differs from exogenous recombinant GH. Recombinant GH supplies the hormone directly and bypasses the pituitary; sermorelin asks the pituitary to release its own. The intermittent-versus-continuous distinction is not a stylistic choice in the research record — it is the empirically observed dosing pattern that maintains response.

The pediatric registration trials

The therapeutic NDA (020443) approved in 1997 rested on pediatric work in idiopathic growth hormone deficiency. The Prakash and Goa 1999 review consolidates that record: once-daily subcutaneous sermorelin at 30 microg/kg at bedtime produced significant, sustained increases in height velocity over 12 months in prepubertal children with idiopathic GHD, with effects maintained over 36 months in subsets ^[1]. The review also notes that sermorelin was less potent than recombinant somatropin at equivalent doses — the clinical question at the time was whether a secretagogue that preserved pituitary control was a useful complement, not whether it would replace recombinant GH entirely ^[1].

The Ishida review summarises the registration-era pediatric program at 30 microg/kg/day subcutaneously for six months in GH-deficient children, with significant gains in GH release and growth velocity replicated across the trials that supported the NDA ^[16]. The pediatric record is the part of the sermorelin literature with the strongest human data.

The elderly-adult studies

Two studies from the late 1990s anchor the adult side of the literature. Vittone and colleagues (1997) gave 1 mg of GHRH(1-29) subcutaneously nightly to healthy elderly men aged 64 to 76; nocturnal GH pulse amplitude and 24-hour integrated GH concentrations rose, and IGF-1 climbed back into the young-adult range ^[3]. Khorram, Laughlin and Yen (1997) ran a 16-week trial of a sermorelin-class GHRH analog ([Nle27]GHRH(1-29)-NH2) at 10 microg/kg subcutaneously nightly in men and women aged 55 to 71 and saw the same pattern: sustained nocturnal GH pulse amplitude and IGF-1 elevations held across the full 16 weeks without tachyphylaxis ^[4]. A companion paper by the same group reported shifts in peripheral immune markers, including increased natural killer cell activity, paralleling the IGF-1 rise ^[15].

These are small trials by modern standards, but they are the cleanest demonstration that GHRH-receptor agonism can restore a more youthful nocturnal GH pattern in older adults — without the loss of pulsatility that exogenous recombinant GH produces.

Pharmacokinetics — a short half-life with a longer downstream

Sermorelin's plasma half-life is roughly 11 to 12 minutes after either intravenous or subcutaneous dosing ^[8]. Peak plasma concentration after subcutaneous administration arrives in 5 to 20 minutes; mean absolute SC bioavailability is approximately 6%; plasma clearance runs 2.4 to 2.8 L/min, largely via dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase ^[8]. The parent peptide is short-lived.

The downstream effects last longer than the molecule. A single nightly pulse drives a 1- to 2-hour GH peak, and the resulting IGF-1 elevation persists for days after dosing stops ^[8]. This kinetic shape — fast clearance, longer downstream — is part of why bedtime dosing aligns with the body's own nocturnal GH window.

A 2012 cognition trial

The Baker and colleagues 2012 trial in Archives of Neurology is the most cited modern human study on GHRH and cognition. The randomized, double-blind, placebo-controlled trial gave 1 mg of GHRH subcutaneously nightly for 20 weeks to older adults — with and without mild cognitive impairment — and reported improvements in executive function and short-term verbal memory composite scores versus placebo, with effects that held for at least 10 weeks after washout ^[16]. The trial is hypothesis-supporting, not definitive, but it is the clearest signal in the modern literature that restoring GH-axis tone in older adults may move cognitive endpoints.

A hypothesis-generating computational signal

Chang and colleagues (2021) ran a high-throughput computational screen across 1,018 glioma transcriptomes and 4,865 drug compounds; sermorelin emerged as the highest-ranked candidate for recurrent glioma, with pathway analysis suggesting cell-cycle inhibition and modulation of immune-checkpoint and M0 macrophage signatures ^[10]. This is a purely in silico signal — no animal or human dosing was performed — and the authors framed it as motivation for pre-clinical testing rather than a clinical claim ^[10]. It is included here for completeness because the result has been widely cited in subsequent compounding literature.

Tolerability in the registration record

The original NDA-era clinical record reported transient injection-site reactions (pain, redness, or swelling) as the most common adverse event, occurring in approximately 16% of patients; of 350 patients exposed to sermorelin in those trials, only three discontinued therapy because of injection-site reactions ^[11]. No consistent systemic safety signals were reported at therapeutic doses, and the isolated GH-axis activation noted earlier (no off-target endocrine perturbation) held across the registration cohort ^[7][11]. The historical safety record is one reason the FDA's 2013 Federal Register finding rested on commercial rather than safety grounds ^[6].

What the literature does not show

It is as important to map the gaps as the findings. The sermorelin record carries a strong pediatric idiopathic-GHD signal anchored by the 1997 NDA, two clean elderly-adult trials from the same decade, one cognition trial from 2012, a 2020 mechanism-and-pharmacokinetics review, and an in silico oncology signal from 2021 ^{[1][3][4][8][10][16]}. Outside those lines, the substantive human literature thins quickly. There is no large modern randomized trial of sermorelin in healthy adults for anti-aging endpoints; there is no large head-to-head against recombinant somatropin in modern pediatric cohorts; and the diagnostic literature has effectively been displaced by arginine and glucagon stimulation testing in the US following the loss of an FDA-approved GHRH product ^[13]. The 2024 PCAC briefing and the 2025 Frier Levitt regulatory analysis frame sermorelin as a long-standing 503A-compounded substance with a stable safety record but acknowledge the absence of recent large prospective trials in adult indications ^[17][19]. Reading the literature honestly means holding both halves — what is well-supported and what is simply not there — in the same view.

How the modern review literature frames it

The 2020 Ishida secretagogue review remains the cleanest modern summary of the sermorelin record because it places the molecule inside the full GHRH-analog and GHRP family — alongside CJC-1295, tesamorelin, ipamorelin, GHRP-2 and GHRP-6 — and traces the receptor pharmacology that distinguishes GHRH agonists (acting on the pituitary GHRHR) from ghrelin-receptor secretagogues (acting on a separate pathway) ^[8][9]. The review's value is not new data; it is the consolidation of fifty years of secretagogue work into one open-access frame that current regulatory analyses cite as a baseline ^[8][9][18]. When this notebook references "the modern literature," the Ishida review is the document doing most of the work.